Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health
US Department of Justice
Farmers Insurance
Chinese Patent Office

Generated: November 19, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: darunavir

« Back to Dashboard

darunavir Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Cipla Ltd darunavir ethanolate 207189 150MG TABLET;ORAL
Hetero Labs Unit Iii darunavir ethanolate 202083 400MG TABLET;ORAL
Mylan Pharms Inc darunavir 202136 400MG TABLET; ORAL
Teva Pharms Usa darunavir ethanolate 202118 400MG TABLET;ORAL
Cipla Ltd darunavir hydrate 206288 75MG TABLET;ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
US Army
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.